ArticleFrontiers in pharmacology2022
Luteolin induces pyroptosis in HT-29 cells by activating the Caspase1/Gasdermin D signalling pathway.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- An Updated Insight into the Phytomolecules Reported for the Treatment of Colon Cancer from 2015 to 2024: Systematic Review.Anti-cancer agents in medicinal chemistry · 2026Pooled it
- Gasdermin-Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer.Cancer science · 2026Review
- Dihydromyricetin (DHM) Inhibits Microglial Pyroptosis and Oxidative Stress After Spinal Cord Injury by Promoting STING-Mediated Autophagy.Biochemical genetics · 2026Article
- Elucidating the mechanism of traditional Chinese medicine formula (Journal of traditional and complementary medicine · 2026Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Wedelolactone induces pyroptosis to suppress retinoblastoma by inhibiting the Nrf2/Keap1 signaling pathway.Medical oncology (Northwood, London, England) · 2025Article
- Triggering Pyroptosis in Cancer.Biomolecules · 2025Review
- Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies.Food science & nutrition · 2025Review
- The Role of Pyroptosis in Colorectal Cancer: From Mechanisms to Therapeutic Opportunities.Cancer management and research · 2025Review
- Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?International journal of molecular sciences · 2024Review
- Inflammasomes in Intestinal Disease: Mechanisms of Activation and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Pyroptotic cell death: an emerging therapeutic opportunity for radiotherapy.Cell death discovery · 2024Review
- Targeting programmed cell death via active ingredients from natural plants: a promising approach to cancer therapy.Frontiers in pharmacology · 2024Review
- Treatment of colorectal cancer by traditional Chinese medicine: prevention and treatment mechanisms.Frontiers in pharmacology · 2024Review
- Luteolin alleviates cerebral ischemia/reperfusion injury by regulating cell pyroptosis.Open medicine (Warsaw, Poland) · 2024Article
- Unlocking the potential of pyroptosis in tumor immunotherapy: a new horizon in cancer treatment.Frontiers in immunology · 2024Review
- Evaluation of the Antitumor Activity of Quaternary Ammonium Surfactants.International journal of molecular sciences · 2023Article
- Mitochondrial dysfunctions induce PANoptosis and ferroptosis in cerebral ischemia/reperfusion injury: from pathology to therapeutic potential.Frontiers in cellular neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin, which is a natural flavonoid, has anti-inflammatory, antioxidant, and anticancer properties. Numerous studies have proven that luteolin inhibits the growth of many types of cancer cells by promoting apoptosis, autophagy, and cell cycle arrest in tumour cells. However,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.